{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:46:30Z","timestamp":1780422390042,"version":"3.54.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105303","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:17:45Z","timestamp":1774599465000},"page":"105303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted cancer therapy: A comprehensive review of strategies in drug development"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6974-5815","authenticated-orcid":false,"given":"Yating","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Ching","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105303_bib1","unstructured":"National cancer institute [Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/targeted-therapies\/approved-drug-list#:\u223c:text=Targeted%20Therapy%20Drug%20List%20by,Approved%20for%20Specific%20Types%20of.(n.d)."},{"key":"10.1016\/j.critrevonc.2026.105303_bib2","unstructured":"U.S. Food & Drug: Drug Approvals and Databases [Available from: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases.(n.d)."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105303_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277266","article-title":"Down-regulation of hepatic expression of GHR\/STAT5\/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor","volume":"17","author":"Abu El-Makarem","year":"2022","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105303_bib4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s40265-019-01208-8","article-title":"Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer","volume":"79","author":"Aggelis","year":"2019","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105303_bib5","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"7820","key":"10.1016\/j.critrevonc.2026.105303_bib6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"issue":"10229","key":"10.1016\/j.critrevonc.2026.105303_bib7","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib9","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1078-0432.CCR-08-2068","article-title":"Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells","volume":"15","author":"Benavente","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105303_bib11","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: Emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105303_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.707317","article-title":"E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points","volume":"9","author":"Bricelj","year":"2021","journal-title":"Front Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105303_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105303_bib15","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.2003.01.039","article-title":"Gefitinib in pretreated non\u2013small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC","volume":"21","author":"Cappuzzo","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3324\/haematol.11288","article-title":"FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab","volume":"92","author":"Carlotti","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41556-022-00892-1","article-title":"Membranes regulate biomolecular condensates","volume":"24","author":"Case","year":"2022","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"issue":"10200","key":"10.1016\/j.critrevonc.2026.105303_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6121","key":"10.1016\/j.critrevonc.2026.105303_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105303_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib24","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib25","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105303_bib27","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1021\/acs.jmedchem.3c00449","article-title":"Molecular Glue Discovery: Current and Future Approaches","volume":"66","author":"Dewey","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105303_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100280","article-title":"Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies","volume":"6","author":"Di Noia","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-006-9168-1","article-title":"The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth","volume":"98","author":"Divisova","year":"2006","journal-title":"Breast Cancer Res Treat."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105303_bib30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib31","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0923-2494(97)84219-8","article-title":"Role for NK-cell-associated Fas ligand in cell-mediated cytotoxicity and apoptosis","volume":"148","author":"Eischen","year":"1997","journal-title":"Res. Immunol."},{"issue":"6836","key":"10.1016\/j.critrevonc.2026.105303_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105303_bib33","article-title":"A study on the interaction and inhibition effect of some natural compound ligands with the 5p21 cancer receptor","author":"F. G","year":"2024","journal-title":"Int. J. Adv. Nat. Sci. Eng. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41746-025-01471-y","article-title":"Convergence of evolving artificial intelligence and machine learning techniques in precision oncology","volume":"8","author":"Fountzilas","year":"2025","journal-title":"npj Digit. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: State-of-the-Art and Future Perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105303_bib36","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105303_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12032-020-01446-x","article-title":"The inhibition effect of natural food supplement active ingredients on TP63 carcinoma cell","volume":"37","author":"G\u00f6kalp","year":"2020","journal-title":"Med Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105303_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12032-020-01428-z","article-title":"The investigation of the healing effect of active ingredients in traditional medicinal plants on lung cancer","volume":"37","author":"G\u00f6kalp","year":"2020","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12032-022-01933-3","article-title":"The curative effect of some natural active compounds for liver cancer","volume":"40","author":"G\u00f6kalp","year":"2022","journal-title":"Med Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/01635581.2021.1895233","article-title":"An Investigation into the Usage of Monosaccharides with GLUT1 and GLUT3 as Prognostic Indicators for Cancer","volume":"74","author":"G\u00f6kalp","year":"2022","journal-title":"Nutr. Cancer"},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2026.105303_bib41","article-title":"Computational insights into the binding interactions of natural compounds with Varroa destructor targets","volume":"332","author":"G\u00f6kalp","year":"2025","journal-title":"Int J. Biol. Macromol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105303_bib42","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1080\/07391102.2024.2302942","article-title":"An investigation into the usage of black cumin derivatives against cancer and COVID-19 as the nature medicine","volume":"43","author":"G\u00f6kalp","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.critrevonc.2026.105303_bib43","first-page":"981","article-title":"The investigation of the interaction of gastric cancer receptors and natural drug ligands in origanum bilgeri","volume":"43","author":"G\u00d6KALP F, ERENLER R, ALMA MH","year":"2025","journal-title":"Sigma J. Eng. Nat. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm.3853","article-title":"Translational value of mouse models in oncology drug development","volume":"21","author":"Gould","year":"2015","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tem.2022.12.001","article-title":"Ghrelin receptor signaling in health and disease: a biased view","volume":"34","author":"Gross","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800292","article-title":"Aminopyrazole-substituted metallophthalocyanines: Preparation, aggregation behavior, and investigation of metabolic enzymes inhibition properties","volume":"352","author":"G\u00fczel","year":"2019","journal-title":"Arch. Pharm. (Weinh."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800292","article-title":"Aminopyrazole-substituted metallophthalocyanines: Preparation, aggregation behavior, and investigation of metabolic enzymes inhibition properties","volume":"352","author":"G\u00fczel","year":"2019","journal-title":"Arch. der Pharm."},{"key":"10.1016\/j.critrevonc.2026.105303_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","article-title":"Artificial intelligence-based multi-omics analysis fuels cancer precision medicine","volume":"88","author":"He","year":"2023","journal-title":"Semin Cancer Biol."},{"issue":"16 Pt 1","key":"10.1016\/j.critrevonc.2026.105303_bib50","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model","volume":"9","author":"Hernandez-Ilizaliturri","year":"2003","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2023.12.008","article-title":"Screening for molecular glues \u2013 Challenges and opportunities","volume":"29","author":"Holdgate","year":"2024","journal-title":"SLAS Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib52","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination Factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib54","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1007\/s11033-020-05685-z","article-title":"The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer","volume":"47","author":"Ji","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105303_bib55","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib56","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acs.bioconjchem.4c00253","article-title":"Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions","volume":"35","author":"Kamaraj","year":"2024","journal-title":"Bioconjug Chem."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105303_bib57","doi-asserted-by":"crossref","first-page":"45898","DOI":"10.18632\/oncotarget.17438","article-title":"Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy","volume":"8","author":"Kasper","year":"2017","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105303_bib58","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/acschemneuro.3c00390","article-title":"Photoactivated Protein Degrader for Optical Control of Synaptic Function","volume":"14","author":"Ko","year":"2023","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/2159-8290.CD-20-0779","article-title":"Opportunities and challenges in drug development for pediatric cancers","volume":"11","author":"Laetsch","year":"2021","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105303_bib60","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","article-title":"Cellular functions of the protein kinase ATM and their relevance to human disease","volume":"22","author":"Lee","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105303_bib61","doi-asserted-by":"crossref","first-page":"11841","DOI":"10.1021\/acs.jmedchem.1c00847","article-title":"GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer","volume":"64","author":"Liang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.critrevonc.2026.105303_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2017.05.002","article-title":"Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer","volume":"401","author":"Liu","year":"2017","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105303_bib64","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-018-0694-6","article-title":"14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin \u03b1v\u03b23 and activating FAK\/PI3K\/AKT signaling","volume":"37","author":"Luo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib66","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40164-024-00529-z","article-title":"Versatile function of NF-\u0138B in inflammation and cancer","volume":"13","author":"Ma","year":"2024","journal-title":"Exp. Hematol. & Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105303_bib68","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105303_bib69","series-title":"The emperor of all maladies: a biography of cancer","author":"Mukherjee","year":"2010"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105303_bib70","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.32604\/or.2024.049918","article-title":"Aldo-keto reductases: role in cancer development and theranostics","volume":"32","author":"Nagini","year":"2024","journal-title":"Oncol. Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105303_bib73","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-59745-570-1_9","article-title":"Analyzing antibody\u2013Fc-receptor interactions","author":"Nimmerjahn","year":"2008","journal-title":"Innate Immun."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105303_bib74","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1074\/jbc.M116.768853","article-title":"Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)","volume":"292","author":"Ohoka","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib75","first-page":"2215","article-title":"Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway","volume":"14","author":"Ottis","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib76","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib77","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Cent. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib78","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105303_bib79","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/ijc.10410","article-title":"Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance","volume":"99","author":"Price-Schiavi","year":"2002","journal-title":"Int J. Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105303_bib80","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1158\/1078-0432.CCR-08-0745","article-title":"A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma","volume":"14","author":"Racila","year":"2008","journal-title":"Clin. Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105303_bib81","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2174\/1871527320666210303111939","article-title":"Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update","volume":"21","author":"Rafiullah","year":"2022","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib82","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/metabo5040571","article-title":"Cancer Metabolism and Drug Resistance","volume":"5","author":"Rahman","year":"2015","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105303_bib83","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.critrevonc.2026.105303_bib84","series-title":"Antibody Fc","first-page":"1","article-title":"Antibody-dependent cellular cytotoxicity (ADCC)","author":"Rom\u00e1n","year":"2014"},{"key":"10.1016\/j.critrevonc.2026.105303_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105303_bib86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105303_bib88","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib89","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/s41467-019-09438-w","article-title":"MEK1\/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance","volume":"10","author":"Sale","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105303_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: Clinical evidence","volume":"47","author":"Sarmento-Ribeiro","year":"2019","journal-title":"Drug Resist Updat"},{"issue":"7015","key":"10.1016\/j.critrevonc.2026.105303_bib91","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105303_bib92","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105303_bib93","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. & Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"issue":"5416","key":"10.1016\/j.critrevonc.2026.105303_bib95","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/244444a0","article-title":"Human\u00d7 mouse somatic cell hybrid clone secreting immunoglobulins of both parental types","volume":"244","author":"Schwaber","year":"1973","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib96","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3565","article-title":"Signals from the lysosome: a control centre for cellular clearance and energy metabolism","volume":"14","author":"Settembre","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105303_bib97","first-page":"459","article-title":"[32] Production and properties of chimeric antibody molecules","volume":"178","author":"Shin","year":"1989"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105303_bib98","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105303_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102251","article-title":"Therapeutic regulation of epigenetics in cancer treatment through drug delivery systems","volume":"56","author":"Su","year":"2024","journal-title":"Nano Today"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105303_bib100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","article-title":"Targeting cell-cycle machinery in cancer","volume":"39","author":"Suski","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040501","article-title":"PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation","volume":"17","author":"Syahputra","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105303_bib102","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk. Res"},{"issue":"7782","key":"10.1016\/j.critrevonc.2026.105303_bib103","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/03602532.2019.1632886","article-title":"Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it","volume":"51","author":"Verma","year":"2019","journal-title":"Drug Metab. Rev."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105303_bib105","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1158\/0008-5472.CAN-17-2344","article-title":"slan(+) Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP","volume":"78","author":"Vermi","year":"2018","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105303_bib106","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1093\/nar\/gkv920","article-title":"The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA","volume":"43","author":"Vickers","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib107","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib108","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10555-022-10066-y","article-title":"The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options","volume":"41","author":"Wang","year":"2022","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105303_bib109","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/1535-7163.MCT-16-0606","article-title":"Suppression of the Growth and Invasion of Human Head and Neck Squamous Cell Carcinomas via Regulating STAT3 Signaling and the miR-21\/\u03b2-catenin Axis with HJC0152","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib111","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2011.03.031","article-title":"The turnover of estrogen receptor \u03b1 by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy","volume":"82","author":"Wardell","year":"2011","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.critrevonc.2026.105303_bib112","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.101127.3","article-title":"C-eA. PROTAC-induced protein structural dynamics in targeted protein degradation","volume":"13","author":"Wu","year":"2025","journal-title":"eLife"},{"issue":"7647","key":"10.1016\/j.critrevonc.2026.105303_bib113","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105303_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119686","article-title":"Precision medicine in colorectal cancer: Leveraging multi-omics, spatial omics, and artificial intelligence","volume":"559","author":"Xu","year":"2024","journal-title":"Clin. Chim. Acta"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105303_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810328","article-title":"Recent Advances in PROTACs for Drug Targeted Protein Research","volume":"23","author":"Yao","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105303_bib116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.critrevonc.2026.105303_bib117","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39030","article-title":"Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12\/13","volume":"7","author":"Zeng","year":"2018","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105303_bib118","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105303_bib119","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.2006.08.8021","article-title":"FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab","volume":"25","author":"Zhang","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105303_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib121","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41392-023-01342-6","article-title":"Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib122","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng. & Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105303_bib123","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biol."}],"updated-by":[{"DOI":"10.1016\/j.critrevonc.2026.105349","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000}},{"DOI":"10.1016\/j.critrevonc.2026.105349","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:47:13Z","timestamp":1778482033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":123,"alternative-id":["S1040842826001903"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105303","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted cancer therapy: A comprehensive review of strategies in drug development","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105303"}}